AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

LISTING OF CLAIM

- 1-12. (cancelled).
- 13. (currently amended) A compound according to Formula III,

or a pharmaceutically acceptable salt thereof, wherein:

- R^{Ia} is selected from halogen, lower perfluoroalkyl, -NO₂, and optionally substituted C₁-4alkyl; and R^{Ib} is selected from halogen, -N(R⁵)R⁵, -SR⁵, perfluoroalkyl, and optionally substituted lower alkyl;
- R³ is independently selected from -H, halogen, trihalomethyl, -CN, -NO2, -OR\$, -N(R\$)OR\$, -ON(R\$)R\$, -N(R\$)N(R\$)R\$, -N(R\$)N(R\$)R\$, -N(R\$)N(R\$)R\$, -S(O)₀₋₂R\$, -SO₂N(R\$)R\$, -CO₂R\$, -C(O)N(R\$)R\$, -N(R\$)SO₂R\$, -N(R\$)C(O)R\$, -N(R\$)CO₂R\$, -C(O)R\$, -C(=NR\$)N(R\$)R\$, -C(=NR\$)N\$, -C(=NR\$)N\$, -C(=NR\$)N\$, -N(R\$)C(=NR\$)N\$, optionally substituted lower alkyl, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylakyl;

R5a is H:

- each R⁵ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or
- two of R⁵, together with the atom or respective atoms to which they are attached, can combine to form an optionally substituted three- to seven-membered heterocyclic;
- each R⁶ is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -NH₂,
 -OR⁵, -N(R⁵)R⁵, -S(O)₀₋₂R⁵, -SO₂N(R⁵)R⁵, -CO₂R⁵, -C(O)N(R⁵)R⁵, -N(R⁵)SO₂R⁵,
 -N(R⁵)C(O)R⁵, -N(R⁵)CO₂R⁵, -C(O)R⁵, optionally substituted lower alkyl,
 optionally substituted aryl, optionally substituted heterocyclyl, optionally
 substituted heterocyclylalkyl, and optionally substituted arylalkyl; or
- two of R⁶, together with the atom or atoms to which they are attached, can combine to form one of an optionally substituted three to seven-membered alicylic, and an optionally substituted three to seven-membered heteroalicylic;
- each R^7 is independently selected from -H, -CN, -NO₂, -N(R^5) R^5 , -OR 5 , -S(O)_{0.2} R^5 , -SO₂N(R^5) R^5 , -CO₂ R^5 , optionally substituted lower alkyl, optionally substituted lower alkenyl, and optionally substituted lower alkynyl; or
- R⁵ and R⁷, together with the atom or atoms to which they are attached, can combine to form a five- to seven-membered optionally substituted heterocyclyl;
- each of X and Y is independently selected from -C(=O)-, $-C(R^6)R^6$ -, -O-, $-N(R^5)$ -, $-C(=NR^7)$ -, and $-S(O)_{0\cdot 2^-}$; provided when X is -O- or $-N(R^5)$ -, then Y cannot contain phenyl, napthyl, cyclohexyl, dihydronapthyl tetrahydronapthyl, or a five-to six-membered heteroaryl, each optionally substituted; and

Q is either =N- or =C(H)-.

14. (previously presented) The compound according to claim 13, wherein R^{1a} is selected from -NO₂, halogen, perfluoroalkyl, haloalkyl, and optionally substituted C_{1-2} alkyl.

- 15. (original) The compound according to claim 14, wherein \mathbb{R}^3 is selected from optionally substituted -O-C_{1.4}alkyl, -O-C_{1.4}perfluoroalkyl, optionally substituted -N(H)C_{1.4}alkyl, optionally substituted -N(C_{1.4}alkyl)C_{1.4}alkyl, optionally substituted -S(O)_{0.2}-C_{1.4}alkyl, and optionally substituted -S(O)_{0.2}-C_{1.4}perfluoroalkyl.
- 16. (original) The compound according to claim 15, wherein Y is either -N(H)- or - $C(R^6)R^6$ -.
- (original) The compound according to claim 16, wherein X is selected from -O-, -N(R⁵)- and -S-.
- 18. (original) The compound according to claim 17, wherein Y is $-C(R^6)R^6$; wherein each R^6 is independently selected from -H, halogen, trihalomethyl, -NH₂, optionally substituted -O-C₁₋₄alkyl, optionally substituted -N(H)C₁₋₄alkyl, optionally substituted -S-C₁₋₄alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.
- 19. (original) The compound according to claim 18, wherein Y is $-C(H)R^6$; wherein R^6 is independently selected from -H, halogen, trihalomethyl, $-NH_2$, optionally substituted $-O-C_{1.4}$ alkyl, optionally substituted $-N(H)C_{1.4}$ alkyl, optionally substituted $-N(H)C_{1.4}$ alkyl, optionally substituted lower alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclylalkyl.
- 20. (original) The compound according to claim 19, wherein Q is =C(H)-.
- 21-28. (cancelled)
- 29. (previously presented) The compound according to claim 13, wherein R^{1a} is selected from halo, lower perfluoroalkyl, -NO₂, and optionally substituted $C_{1.4}$ alkyl.
- 30-33, (Cancelled)
- 34. (previously presented) A compound selected from Table 3.

Table 3

	Table 3		
Entry	Name	Structure	
1	2-[(3-cyano-4,6-dimethyl-5- nitropyridin-2-yi)oxy]-N-[3- (trifluoromethyl)phenyl]acetamide	O ₂ N CN CF ₃	
5	N ² -[2-amino-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	H ₂ N N N CF ₃	
7	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [3-(methyloxy)phenyl]acetamide	H ₂ N N S T H	
9	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- (4-chlorophenyl)acetamide	S N H ₂ N N S T H	
11	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- (3-chlorophenyl)acetamide	H ₂ N N H CI	

Entry	Name	Structure
14	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3-(trifluoromethyl)phenyl]acetamide	S N H F F F F F
16	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- methyl-N-[3- (trifluoromethyl)phenyl]acetamide	H ₂ N N CF ₃
17	N ² -[4-amino-6-(methylthio)-1,3,5- triazin-2-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S N N N CF3
20	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	H ₂ N N N CF ₃
30	2-amino-4-({2-[2,5- bis(methyloxy)phenyl]-2- oxoethyl}thio)-6- (methylthio)pyrimidine-5-carbonitrile	H ₂ N N S
31	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-fluoro-3- (trifluoromethyl)phenyl]acetamide	H ₂ N S N H CF ₃

Entry	Name	Structure
34	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-chloro-3- (trifluoromethyl)phenyl]acetamide	S CN H ₂ N CF ₃
35	2-amino-4-(methylthio)-6-({2-oxo-1- [3-(trifluoromethyl)phenyl]pyrrolidin- 3-yl}thio)pyrimidine-5-carbonitrile	S CN CF3
36	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [6-(trifluoromethyl)pyridin-2- yl]acetamide	H ₂ N N S N N CF ₃
37	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [4-(trifluoromethyl)pyridin-2- yl]acetamide	S CN H ₂ N CF ₃
41	2-{[2-(acetylamino)-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [3-(trifluoromethyl)phenyl]acetamide	S N H F F
42	(2S)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]propanamide	-s HN-FF

Entry	Name	Structure
45	2-{[2-amino-5-formyl-6- (methylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	ST S S S S S S S S S S S S S S S S S S
46	2-{[2-amino-5-formyl-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3-(trifluoromethyl)phenyl]acetamide	ST-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-S-
47	2-{[4-amino-6-(methylthio)-1,3,5- triazin-2-yl]oxy}-N-[3- (trifluoromethyl)phenyl]acetamide	S O H F F
54	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-(methyloxy)-5- (trifluoromethyl)phenyl]acetamide	H ₂ N N S CF ₃
55	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-chloro-5- (trifluoromethyl)phenyl]acetamide	H ₂ N N CI

Entry	Name	Structure
58	N²-[2-amino-5-[(E)- hydrazonomethyl]-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	NH ₂ N N N N N N N N N N N N N N N N N N N
59	N²-[2-amino-5-[(E)- (hydroxyimino)methyl]-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	NH ₂ N N N N N N N N N N N N N N N N N N N
60	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	NH ₂ N N N N N N N N N N N N N N N N N N N
61	2-{[2-amino-5-cyano-6- (methylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	H ₂ N N S N F F
62	2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]thio}-N- [2-amino-5- (trifluoromethyl)phenyl]acetamide	H ₂ N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
63	2-amino-4-(methylthio)-6-({[6- (trifluoromethyl)-1H-benzimidazol-2- yl]methyl}thio)pyrimidine-5- carbonitrile	H ₂ N S N F F
64	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	S N H ₂ N N H N F F
65	N ² -[5-cyano-2-(methylamino)-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S N H F F
66	2-{[2-amino-5-cyano-6- (dimethylamino)pyrimidin-4-yl]thio}- N-[3- (trifluoromethyl)phenyl]acetamide	H ₂ N N S N F F
67	(S)-1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]prolinamide	S N O F F F
68	(2R)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]propanamide	-s N F F F F

Entry	Name	Structure
69	1-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-N- [3- (trifluoromethyl)phenyl]cyclopropane carboxamide	-S O N F F F
70	(2S)-2-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]oxy}-3- methyl-N-[3- (trifluoromethyl)phenyl]butanamide	H ₂ N O HN F F
72	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]glycinamide	S N H F F
73	1-{[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]amino}- N-[3- (trifluoromethyl)phenyl]cyclopropane carboxamide	-S H O N H F F
74	N ² -[2-amino-5-cyano-6- (methylsulfinyl)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	S ² O N H ₂ N N H O F F

Entry	Name	Structure
75	N²-[2-amino-5-cyano-6- (methylsulfonyl)pyrimidin-4-yl]-N- [3-(trifluoromethyl)phenyl]-L- alaninamide	O-SO N H N H N H N H N H N H N H N H N H N
76	N ² -(5-cyano-2-morpholin-4- ylpyrimidin-4-yl)-N-[3- (trifluoromethyl)phenyl]glycinamide	N H O F F
78	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N H CF ₃
79	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[2- (methyloxy)-5- (trifluoromethyl)phenyl]-L- alaninamide	H ₂ N H CF ₃
80	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[2- chloro-5-(trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N H CF ₃
83	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-D- alaninamide	H ₂ N N H CF ₃

Entry	Name	Structure
84	2-[(2-amino-5-cyano-6-morpholin-4-yl)pyrimidin-4-yl)thio]-N-[3- (trifluoromethyl)phenyl]acetamide	NH2 NH2 SOO
85	(R)-1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]prolinamide	S N O N F F
86	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- ornithinamide	S CN NH2 N N N N N CF3
87	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2-[2- (dimethylamino)ethyl]-N-[3- (trifluoromethyl)phenyl]glycinamide	S CN H ₂ N CF ₃
88	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N H CF ₃

Entry	Name	Structure
89	N ² -(2,6-diamino-5-cyanopyrimidin-4-yl)-N-[3-(trifluoromethyl)phenyl]-L-alaninamide	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
90	N ² -(2-amino-5-cyanopyrimidin-4-yl)- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
91	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- methyl-N-[3- (trifluoromethyl)phenyl]-L- alaninamide	S CN H CF3
93	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-1,2- dimethyl-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	10 H ₂ N CF ₃
94	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- amino-5-(trifluoromethyl)phenyl]-L- alaninamide	S CN H CF3
95	ethyl [1-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-2-({[3- (trifluoromethyl)phenyl]amino}carbo nyl)hydrazino]acetate	S CN H H CF3

Entry	Name	Structure
96	2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-2- methyl-N-[3- (trifluoromethyl)phenyl]hydrazinecar boxamide	S CN H ₂ N N CF ₃
100	N ² -[5-cyano-2-(methylthio)pyrimidin-4-yl]- N-[3-(trifluoromethyl)phenyl]glycinamide	S N H CF3
101	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2- (tetrahydro-2H-pyran-4-ylmethyl)-N-[3- (trifluoromethyl)phenyl]glycinamide	S CN H ₂ N CF ₃
102	N ² -(2-amino-5-cyano-6-[[2- (dimethylamino)ethyl]oxy)pyrimidin-4-yl)- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	H ₂ N N CF ₃
103	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-6-{[(1,1- dimethylethyl)oxy]carbonyl}-N-[3- (trifluoromethyl)phenyl]-L-lyslnamide	CF ₃ NH ₂ NH NH NH NH NH NH

Entry	Name	Structure
104	2-amino-4-(methylthio)-6-(methyl((1S)-1- [6-(trifluoromethyl)-1H-benzimidazol-2- yl]ethyl]amino)pyrimidine-5-carbonitrile	NH ₂ NH ₂ CF ₃
105	N ² -[2-amino-5-cyano-6- (methytthio)pyrimidin-4-ylj-N-2-[2- (tetrahydro-2H-pyran-4-yl)ethyl]-N-[3- (trifluoromethyl)phenyljglycinamide	NH ₂
106	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-[3-([2- (diethylamino)ethyl]amino}-5- (trifluoromethyl)phenyl]-L-alaninamide	F ₂ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
107	2-amino-4-(methylthio)-6-(((1S)-1-[6- (trifluoromethyl)-1H-benzimidazol-2- yl]ethyl)amino)pyrimidine-5-carbonitrile	-S NH NH F
108	2-{2-amino-5-cyano-6-[1-(3- trifluoromethyl-phenylcarbamoyl)-1S- ethylamino]-pyrimidin-4-ylamino)-N-{3- trifluoromethyl-phenyl}-2S-propionamide	HN CF ₃ H ₂ N N N CF ₃ CF ₃

Γa.		

Entry	Name	Structure
109	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2-methyl-N- (3-methylphenyl)glycinamide	NH2 N N N N N N N N N N N N N N N N N N
110	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2-methyl-N- [3-(1-methylethyl)phenyl]glycinamide	S Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
111	N ² -[2-amino-5-cyano-6- (methythio)pyrimidin-4-y]-N-5- [imino(nitroamino)methy]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	NH ₂ NNO ₂ NNO ₂ CF ₃
112	methyl 3-{{N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alanyl}amino)-5-{trifluoromethyl)benzoate	S NH2 N N N N CF3 CO ₂ CH ₃
113	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-(3- nitrophenyl)-L-alaninamide	S NH2 N NO2
114	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-lysinamide	NH2 NH2 CF3

h	

Entry	Name	Structure
115	N ² -[2-amino-5-cyano-6- (propyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	$ \begin{array}{c c} & \text{NH}_2 \\ & \text{CF}_3 \end{array} $
117	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyi]-L-argininamide	NH ₂ NH ₂ NH NH CF ₃
118	N ² -[2-amino-5-cyano-6- (methylsulfinyl)pyrimidin-4-yl]-N-2-methyl- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	NH2 N N N N N N N N N N N N N N N N N N N
119	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-2-methyl-N- [3-(trifluoromethyl)phenyl]-L-alaninamide	NH ₂ NH ₂ NH ₂ NH ₂ CF ₃
120	N ² -[2-amino-5-cyano-6- (propyloxy)pyrimidin-4-yl]-N-2-methyl-N- [3-(trifluoromethyl)phenyl]-L-alaninamide	NH2 NH2 CN CN CF3
121	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yi]-N-2-methyl-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	NH2 NNNNNN CNNNNNNN CF3

Entry	Name	Structure
122	N ² -{2-amino-5-cyano-6-[(1- methylethyl)oxy]pyrimidin-4-y}-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	NH ₂ N N N N N N N N N N N N N N N N N N N
123	N-5-acetyl-N-2-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	S CN CF3
124	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-(3- aminophenyl)-L-alaninamide	S NH ₂
125	3-{{N-[2-amino-5-cyano-6- (methylthlo)pyrimidin-4-yl]-L- alanyl)amino)-N-[2-(dimethylamino)ethyl]- 5-{trifluoromethyl)benzamide	NH ₂ NH ₂ NH _N NH CF ₃
126	2-(methyloxy)ethyl ((4S)-4-[[2-amino-5- cyano-6-(methylthio)pyrimidin-4- yl)amino)-5-oxo-5-[[3- (trifluoromethyl)phenyl]amino)pentyl)carb amate	NH ₂ NH ₂ NH ₂ NH ₂ CF ₃

Entry	Name	Structure
127	2-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]hydrazinecarboxa mide	NH ₂
128	1,1-dimethylethyl ((4\$)-4-[[2-amino-5-cyano-6-(ethyloxy)pyrimidin-4-yl]amino}-5-oxo-5-[[3- (trifluoromethyl)phenyl]amino)pentyl)carb amate	NH2 CF3
130	3-{{N-{2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-methyl-L- alanyl}amino)-N-{2- (dimethylamino)ethyl]-5- (trifluoromethyl)benzamide	Chiral H ₂ N CH ₃ H CH ₃ H CF ₃ HN O H ₃ C CH ₃
131	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-methyl-L- alanyl)amino)-N-[3-(4-methylpiperazin-1- yl)propyl]-5-(trifluoromethyl)benzamide	S.CH ₃ N Chiral N CH ₃ H CH ₃ H CH ₃ O H ₃ C N H ₃ C N N CH ₃ O

Entry	Name	Structure
132	N ² -{2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2~-methyl- N-{3-{(trifluoromethyl)oxy]phenyl}-L- alaninamide	S.CH ₃ N Chiral
133	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-(3- bromophenyi)-N-2methyl-L- alaninamide	H ₃ C·S Chiral H ₂ N CH ₃ N CH ₃ N Br CH ₃ O
134	N ² -{2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-{2-([2- (dimethylamino)ethyl]oxy)-5- [(trifluoromethyl)oxy]phenyl)-N-2 methyl-L-alaninamide	S.CH ₃ CH ₃ H ₂ N F F
135	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl)-N-methyl-L- alanyl)amino)-N-[2-morpholin-4-ylethyl)- 5-(trifluoromethyl)benzamide	S.CH ₃ N CF ₃ H N CH ₃ N CF ₃ CH ₃ N CF ₃

Entry	Name	Structure
136	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yi]-N-2~-methyl-N- [3-(trifluoromethyl)phenyl]-L-lysinamide	CH ₃ NH ₂ Chiral
137	N ² -[2-amino-5-cyano-6- (methytthio)pyrimidin-4-yl]-N-[3-[[2- (dimethylamino)ethyl]oxy]-5- (trifluoromethyl)phenyl]-L-alaninamide	S.CH ₃ CH ₃ H F F O N CH ₃ CH ₃ CH ₃ CH ₃ CH ₃
138	(2S)-2-[[2-amino-5-cyano-6- (methylthio).pyrimldin-4-yl]amino)-3-oxo- 3-[[3-(trifluoromethyl).phenyl]amino).propyl acetate	H ₂ C·S CH ₃ Chiral
139	N²-[2-amino-5-cyano-6- (methyithio)pyrimidin-4-yl]-N-1~-[3- (trifluoromethyl)phenyl]-L-glutamamide	H ₃ C·s H ₂ N O Christ N N N H CF ₃
140	2-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]hydrazinecarboxa mide	H ₃ C. N H H F F F F F F F F F F F F F F F F F

Τа	h	2

Entry	Name	Structure
141	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alanyl}amino)-N-hydroy-5- (trifluoromethyl)benzamide	S.CH ₃ N Chiral H ₂ N N CH ₃ H HN O OH
142	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L-alarinamide	H ₃ C·S Chral
143	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-5-morpholin-4- yl-N-[3-(trifluoromethyl)phenyl]-L- norvalinamide	H ₃ C· _S N H F F F
144	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-5~-[2- (methyloxy)ethyl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	S.CH NH H.2N N H CF3

Entry	Name	Structure
145	3-({N-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-L- alanyl}amino)-5-(trifluoromethyl)benzoic acid	S.CH ₃ N CH ₃ H H ₂ N N N CF ₃ HOOO
146	methyl N~2~-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutaminate	H ₃ C·S H ₃ C·O O Chiral N O C C H ₂ N O C C C C C C C C C C C C C C C C C C
147	N ⁵ -(aminocarbonyl)-N~2~-[2-amino-5-cyano-6-(methylthio)pyrimidin-4-yi]-N-[3-(trifluoromethyl)phenyl]-L-omithinamide	O NH ₂ Chief
148	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	CH ₃ Chiral
149	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha-glutamine	H ₃ C·s HO Chiral

Entry	Name	Structure
150	N ² -{2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl}-N-[3- (trifluoromethyl)phenyl]-L-serinamide	CH ₃ Chiral
151	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl)-O- (phenylmethyl)-N-[3- (trifluoromethyl)phenyl]-L-serinamide	CHral CHral CHral CHral CHral
152	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-argininamide	CH ₃ H ₂ N NH Chiral
153	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-2~-methyl- N ⁶ -[(phenylmethyl)oxy[carbonyl]-N-[3- (trifluoromethyl)phenyl]-L-lysinamide	Chiral H ₃ C. S H ₂ N CH ₃ O Chiral

Entry	Name	Structure
154	N-a-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3- (trifluoromethyl)phenyi]-L-tyrosinamide	H ₃ C O CN H CHIAN
155	N ⁵ -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	H ₃ C. S N HN O NH ₂
156	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yi]-N-6-,N-6 dimethyl-N-[3-(trifluoromethyl)phenyl]-L- lysinamide	CH ₃ H ₃ C·N·CH ₃ Chrai
157	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3-[(4- methylpiperazin-1-yl)carbonyl]-5- (trifluoromethyl)phenyl]-L-alaninamide	CH ₃ Chiral

Entry	Name	Structure
158	3-({N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yi]-L-alanyi)amino)- N-[3-pyroidin-1-yipropyi)-5- (trifluoromethyl)benzamide	Chiral Ch
159	3-{{N-{2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-1-alany)}amino}- N-{2-morpholin-4-ylethy}-5- (trifluoromethyl)benzamide	Chiral Chiral Chiral CF ₃
160	3-({N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-1-alanylylamino)- N-[2-(dimethylamino)ethyl]-5- (trifluoromethyl)benzamide	Chiral CH ₃ H CF ₃ H ₂ N CF ₃ HN O H ₃ C ^{-N} ·CH ₃

Table 3

Entry	Name	Structure
161	3-({N-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]]-L-alanyi)jamino)- N-[3-(4-methylpiperazin-1-yl)propyl]-5- (trifluoromethyl)benzamide	CH ₃ Chiral CH ₃ H CH ₃ H CH ₃ H CF ₃ H CF ₃
162	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-2methyl- N ⁶ -[[(phenylmethyl)oxy]carbonyl]-N-[3- (trifluoromethyl)phenyl]-L-lysinamide	Chiral CH ₃ H ₂ N CH ₃ H ₂ N CH ₃ CH ₃ CH ₃ H ₂ N CH ₃ C
163	1,1-dimethylethyl ((4\$)-4-{[2-amino-5- cyano-6-(ethyloxy)pyrimidin-4-yljamino}- 5-oxo-5-{[3- (trifluoromethyl)phenyljamino)pentyl)carb amate	CH ₃ OOO NH H ₂ N NH H ₂ N NH FF

Entry	Name	Structure
164	(2S)-2-[[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]amino)-3-oxo-3- ([3-(trifluoromethyl)phenyl]amino)propyl acetate	CH3 CHral
165	phenylmethyl N~2~[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutaminate	Chiral Chiral
166	N ² , N ⁵ -diacetyl-N~2~-[2-(acetylamino)-5- cyano-6-(methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	S.CH ₃ NH H ₃ C N N CF ₃
167	2-(methyloxy)ethyl ((4S)-4-[[2-amino-5- cyano-6-(methylthio)pyrimidin-4- yl]amino)-5-oxo-5-[[3- (trifluoromethyl)phenyl]amino)pentyl)carb amate	O O CH3CHrad

Entry	Name	Structure
168	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-5-morpholin-4-yl- N-[3-(trifluoromethyl)phenyl]-L- norvalinamide	CHral
169	N-((4S)-4-{[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]amino)-5-oxo-5- {[3-{trifluoromethyl)phenyl]amino}pentyl)- N,N-dimethylmethanaminium	CH ₃ CH _C H ₃ Chiral
170	Methyl N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-ylj-N-[3- (trifluoromethyl)phenyl]-1-alpha- glutaminate	CH ₃ Chirel OH ₃ COO H ₂ N H ₂ N CF ₃
171	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-y]-N-6~,N-6~- dimethyl-N-[3-(trifluoromethyl)phenyl]-L- lysinamide	H ₃ C. _N .CH ₃ Chiral
172	N ² -{2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y -N-2~-methyl-N- {3-{(trifluoromethyl)oxylphenyl}-L- alaninamide	Chiral Chiral Chiral P Chiral

`a		

Entry	Name	Structure
173	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yll-N-[3- (trifluoromethyl)phenyl]-L-alpha-glutamine	CH ₃ HO Chiral
174	N~2~-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-(3- bromophenyl)-N~2~-methyl-L- alaninamide	Chiral Chiral Chiral Chiral Chiral Chiral
175	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yi]- N ¹ -[3- (trifluoromethyl)phenyl]-L-glutamamide	CH ₃ H ₂ N O Chiral
176	N²-[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	CH ₃ Chiral
177	2-(2-amino-5-cyano-6- ethoxypyrimidin-4-ylamino)-5- hydrazinyl-5-oxo-N-(3- (trifluoromethyl)phenyl)pentanamide	CH ₃ NH ₂ Chiral

Entry	Name	Structure
178	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-3- (dimethylamino)-N-[3- (trifluoromethyl)phenyl]-L-alaninamide	H ₃ C· CH ₃ CH ₃ FF FF H ₂ N N H O
179	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-y l-N-[3-([2- (dimethylamino)ethyl]oxy]-5- (trifluoromethyl)phenyl]-L-alaninamide	H ₂ N N H F F CH ₃ CH ₃ CH ₃ CH ₃ CH ₃
180	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3-{[2- (dimethylamino)ethyl]oxy}-5- (trifluoromethyl)phenyl]-L-alaninamide	Chiral N CH ₃ H ₂ N N H O N CH ₃ CH ₃ CH ₃
181	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-y]-N-(3- bromophenyl)- N ² -methyl-L-alaninamide	H ₃ C O CNot H ₃ H Br CH ₃ O Br

Entry	Name	Structure
182	phenylmethyl N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-alpha- glutaminate	H ₃ C.s O O H CF ₃
183	N ² -[2-amino-5-cyano-6- (methylthio]pyrimidin-4-yi]-O- (phenylmethyl)-N-[3- (trifluoromethyl)phenyl]-L-serinamide	H ₃ C·S CN O H CF ₃
184	N²-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-5~, N~5~- bis[2-(methyloxy)ethyl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	CH ₃ Chral
185	1,1-dimethylethyl ((4S)-4-[[2-amino-5- cyano-6-(methyloxy)pyrimidin-4- yljamino)-5-oxo-5-[[3- (trifluoromethyl)phenyljamino)pentyl)carb amate	H ₂ N N H O CH ₃ CF ₃

Entry	Name	Structure
186	N ⁵ -acetyl- N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	CH ₃ O CH ₃ Chied
187	N ⁵ acetyl- N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yi]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	O CH ₃ Chiral O CH ₃ NH H ₂ N N CF ₃
188	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yi]- N ² -methyl-N- {3-[(trifluoromethyl)xy]phenyi)-L- alaninamide	H ₂ N N OCF ₃
189	methyl 3-{{N-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-y]-L- alanyl}amino)-5-{trifluoromethyl)benzoate	CH ₃ N CH ₃ H H ₂ N N N CF ₃

Entry	Name	Structure
190	3-{{N-[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-y]-L- alanyl}amino)-N-[2-(dimethylamino)ethyl]- 5-(trifluoromethyl)benzamide	Chiral Chiral Chiral Chiral Chiral Chiral H ₂ N N H ₃ C N H ₃ C N CH ₃
191	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-3-morpholin-4- yl-N-[3-(trifluoromethyl)phenyl]-L- alaninamide	H ₂ C. S Chiral
192	N ² -[2-amino-5-cyano-6- (methyloxy)pyrimidin-4-yl]-3-morpholin-4- yl-N-[3-(trifluoromethyl)phenyl]-L- alaninamide	H ₃ C. Chiral
193	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl]-3-morpholin-4-yl- N-[3-(trifluoromethyl)phenyl]-L- alaninamide	CHral
194	N ⁵ -(aminocarbonyl)- N ² -[2-amino-5- cyano-6-(ethyloxy)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	ONH ₂ Chiral

٦	ſя	h	la	3	

Entry	Name	Structure .
195	N~2~-[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-[3- (trifluoromethyl)phenyl]-D-lysinamide	SME NH2 Chiral
196	N ² -[2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-y]-N-[3- (trifluoromethyl)phenyl]-D-lysinamide	OEt NH2 Christ
197	N ² -{2-amino-5-cyano-6- (ethyloxy)pyrimidin-4-yl}-0-methyl-N-[3- (trifluoromethyl)phenyl]-L-serinamide	CH ₃ Christ
198	N ² -[2-amino-5-cyano-6- (methylthio)pyrimidin-4-yl]-N-5~- (methylsulfonyl)-N-[3- (trifluoromethyl)phenyl]-L-ornithinamide	\$-CH ₃

- 35. (previously presented) A pharmaceutical composition comprising the compound according to claims 13 and a pharmaceutically acceptable carrier.
- 36. (cancelled).

- 37. (currently amended) A method of modulating in vivo activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising a compound according to claim 13, wherein the kinase is p7086K.
- 38. (cancelled).
- (currently amended) The method according to claim 38 37, wherein modulating the in vivo activity of p70S6K comprises inhibition of p70S6K.
- 40. (previously presented) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising a compound according to claim 13.
- 41. (previously presented) A method of screening for modulator of a p70S6 kinase, the method comprising combining either a compound according to claim 13, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.
- 42. (previously presented) A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of: the compound according to claim 13.
- 43. (currently amended) A method of inhibiting abnormal metabolic activity in a cell, the method comprising administering an effective amount of: the compound according to any of claim 13.